These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 24080892)

  • 21. Pneumococcal vaccination in adults: does it really work?
    Pitsiou GG; Kioumis IP
    Respir Med; 2011 Dec; 105(12):1776-83. PubMed ID: 21816596
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emergence of Streptococcus pneumoniae serotype 15A after the introduction of the conjugate vaccine in Victoria.
    Strachan JE; Rowe SL; Dunne EM; Hogg GG
    Med J Aust; 2013 Oct; 199(7):461-3. PubMed ID: 24099202
    [No Abstract]   [Full Text] [Related]  

  • 23. [Pneumococcal vaccination and serotype replacement: Do we need new vaccination concepts?].
    Kenzel S; Hufnagel M; Berner R; Henneke P
    Dtsch Med Wochenschr; 2010 Jun; 135(23):1198-200. PubMed ID: 20480453
    [No Abstract]   [Full Text] [Related]  

  • 24. [Repercussion of anti-pneumococcal vaccine in resistances].
    Granizo Martínez JJ
    Rev Esp Quimioter; 2007 Mar; 20(1):128-30. PubMed ID: 17530046
    [No Abstract]   [Full Text] [Related]  

  • 25. Effect of pneumococcal polysaccharide vaccine on nonbacteremic pneumococcal pneumonia.
    Weiser JN; Austrian R
    Clin Infect Dis; 2007 Apr; 44(8):1139-40; author reply 1140-1. PubMed ID: 17366469
    [No Abstract]   [Full Text] [Related]  

  • 26. Understanding the burden of pneumococcal disease in adults.
    Blasi F; Mantero M; Santus P; Tarsia P
    Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():7-14. PubMed ID: 22882668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines.
    Lynch JP; Zhanel GG
    Curr Opin Pulm Med; 2010 May; 16(3):217-25. PubMed ID: 20375783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Vaccination against Streptococcus pneumoniae in solid organ transplant recipients].
    Fiorante S; López-Medrano F; Ruiz-Contreras J; Aguado JM
    Enferm Infecc Microbiol Clin; 2009 Dec; 27(10):589-92. PubMed ID: 19361892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Incidence of invasive pneumococcal infection in children aged less than two years. The heptavalent pneumococcal conjugate vaccine. Situation in Spain].
    Blanco Quirós A; Giménez Sánchez F; Asensi Botet F; Bernaola Iturbe E; Martín Fde J; García Pérez J; Garcés Sánchez M; Gómez Campderá JA; Picazo JJ; Pineda Solas V;
    An Esp Pediatr; 2002 Oct; 57(4):287-9. PubMed ID: 12392660
    [No Abstract]   [Full Text] [Related]  

  • 30. Cost-effectiveness of universal pneumococcal vaccination for infants in Italy.
    Marchetti M; Colombo GL
    Vaccine; 2005 Aug; 23(37):4565-76. PubMed ID: 15992969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in tennessee after introduction of the pneumococcal conjugate vaccine.
    Talbot TR; Poehling KA; Hartert TV; Arbogast PG; Halasa NB; Mitchel E; Schaffner W; Craig AS; Edwards KM; Griffin MR
    Clin Infect Dis; 2004 Sep; 39(5):641-8. PubMed ID: 15356776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic Evidence of Pneumococcal Vaccination in Older Adults: Uncertain Modelling or Competitive Tendering?
    Garattini L; Padula A; Da Costa MR
    Pharmacoeconomics; 2016 Mar; 34(3):221-4. PubMed ID: 26518294
    [No Abstract]   [Full Text] [Related]  

  • 33. Pneumococcal resistance in the postvaccine era.
    Temime L; Guillemot D; Boëlle PY
    Pediatr Infect Dis J; 2006 Apr; 25(4):382-3. PubMed ID: 16568001
    [No Abstract]   [Full Text] [Related]  

  • 34. Antibiotic resistance in Latin America: a cause for alarm.
    Valenzuela MT; de Quadros C
    Vaccine; 2009 Aug; 27 Suppl 3():C25-8. PubMed ID: 19540634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe.
    Fedson DS; Nicolas-Spony L; Klemets P; van der Linden M; Marques A; Salleras L; Samson SI
    Expert Rev Vaccines; 2011 Aug; 10(8):1143-67. PubMed ID: 21810065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Issues in pneumococcal disease and pneumococcal conjugate vaccines: highlights of the 27th meeting of ESPID, Brussels, Belgium, June 9-13, 2009.
    Adam D
    Vaccine; 2009 Nov; 27(50):7133-7. PubMed ID: 19883868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model.
    De Wals P; Black S; Borrow R; Pearce D
    Clin Ther; 2009 Oct; 31(10):2152-69. PubMed ID: 19922887
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The volatile nature of pneumococcal serotype epidemiology: potential for misinterpretation.
    Black S
    Pediatr Infect Dis J; 2010 Apr; 29(4):301-3. PubMed ID: 19935444
    [No Abstract]   [Full Text] [Related]  

  • 39. Epidemiology of Streptococcus pneumoniae.
    Varon E
    Med Mal Infect; 2012 Aug; 42(8):361-5. PubMed ID: 22819510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain).
    Navas E; Salleras L; Gisbert R; Domínguez A; Timoner E; Ibáñez D; Prat A
    Vaccine; 2005 Mar; 23(17-18):2342-8. PubMed ID: 15755625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.